Polatuzumab Vedotin

Polatuzumab vedotin (INN;[4] brand name Polivy, is an antibody-drug conjugate or ADC designed for the treatment of cancer.[5] The US Food and Drug Administration approved polatuzumab vedotin in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab.[6][7] The drug was developed by Genentech and Roche.[not verified in body] History In June 2019, polatuz... [wikipedia]